[1]余晨曦,滕皋军.经导管动脉化疗栓塞术抵抗研究进展 [J].介入放射学杂志,2017,(12):1063-1067.
　YU Chenxi,TENG Gaojun.Transarterial chemoembolization refractory： current research progress[J].journal interventional radiology,2017,(12):1063-1067.
点击复制

经导管动脉化疗栓塞术抵抗研究进展 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年12期
页码:
1063-1067
栏目:
专论
出版日期:
2017-12-25

文章信息/Info

Title:
Transarterial chemoembolization refractory： current research progress
作者:
余晨曦;  滕皋军
Author(s):
YU Chenxi;  TENG Gaojun
Medical College， Southeast University， Nanjing， Jiangsu Province 210009， China
关键词:
【关键词】 肝细胞肝癌;  经导管动脉化疗栓塞术;  抵抗
文献标志码:
A
摘要:
【摘要】 经导管动脉化疗栓塞术（TACE）是巴塞罗那临床肝癌（BCLC）分期B期肝细胞肝癌（HCC）患者推荐治疗方案，已广泛应用于临床。但越来越多文献报道表明，TACE作为一种姑息性治疗方案存在缺陷，如多次TACE治疗后肝癌病灶控制不佳，因此有学者提出“TACE抵抗”观点。本文就TACE抵抗概念及其治疗进展作一论述。

参考文献/References:

［1］ Torre LA， Bray F， Siegel RL， et al. Global cancer statistics， 2012［J］. CA Cancer J Clin， 2015， 65： 87-108.
［2］ Mor E， Tur-Kaspa R， Sheiner P， et al. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation［J］. Ann Intern Med， 1998， 129： 643-653.
［3］ Parkin DM. Global cancer statistics in the year 2000［J］. Lancet Oncol， 2001， 2： 533-543.
［4］ 陈万青， 郑荣寿， 张思维， 等． 2013年中国恶性肿瘤发病和死亡分析［J］． 中国肿瘤， 2017， 26： 1-7．
［5］ Chen JG， Zhang SW. Liver cancer epidemic in China： past， present and future［J］. Semin Cancer Biol， 2011， 21： 59-69.
［6］ Huang HY， Shi JF， Guo LW， et al. Expenditure and financial burden for common cancers in China： a hospital-based multicentre cross-sectional study［J］. Lancet， 2016， 388（SI）： S10.
［7］ Cabibbo G， Enea M， Attanasio M， et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma［J］. Hepatology， 2010， 51： 1274-1283.
［8］ Okuda K， Ohtsuki T， Obata H， et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients［J］. Cancer， 1985， 56： 918-928.
［9］ Llovet JM， Bruix J. Prospective validation of the Cancer of the Liver Italian Program（CLIP） score： a new prognostic system for patients with cirrhosis and hepatocellular carcinoma［J］. Hepatology， 2000， 32： 679-680.
［10］ Leung TW， Tang AM， Zee B， et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system， the Okuda staging system， and the Cancer of the Liver Italian Program staging system： a study based on 926 patients［J］. Cancer， 2002， 94： 1760-1769.
［11］ Vauthey JN， Lauwers GY， Esnaola NF， et al. Simplified staging for hepatocellular carcinoma［J］. J Clin Oncol， 2002， 20： 1527-1536.
［12］ Llovet JM， Bru C， Bruix J. Prognosis of hepatocellular carcinoma： the BCLC staging classification［J］. Semin Liver Dis， 1999， 19： 329-338.
［13］ Lencioni R. Chemoembolization in patients with hepatocellular carcinoma［J］. Liver Cancer， 2012， 1： 41-50.
［14］ Minami Y， Yagyu Y， Murakami T， et al. Tracking navigation imaging of transcatheter arterial chemoembolization for hepatocellular carcinoma using three-dimensional cone-beam CT angiography［J］. Liver Cancer， 2014， 3： 53-61.
［15］ European Association for the Study of the Liver， European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines： management of hepatocellular carcinoma［J］. J Hepatol， 2012， 56： 908-943.
［16］ Llovet JM， Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma： chemoembolization improves survival［J］. Hepatology， 2003， 37： 429-442.
［17］ Wang YX， De Baere T， Idee JM， et al. Transcatheter embolization therapy in liver cancer： an update of clinical evidences［J］. Chin J Cancer Res， 2015， 27： 96-121.
［18］ Murata S， Mine T， Sugihara F， et al. Interventional treatment for unresectable hepatocellular carcinoma［J］. World J Gastroenterol， 2014， 20： 13453-13465.
［19］ Lencioni R. Loco-regional treatment of hepatocellular carcinoma［J］. Hepatology， 2010， 52： 762-773.
［20］ Cheng AL， Amarapurkar D， Chao Y， et al. Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma： Consensus recommendations and review by an International Expert Panel［J］. Liver Int， 2014， 34： 174-183.
［21］ Brown DB， Geschwind JF， Soulen MC， et al. Society of interventional radiology position statement on chemoembolization of hepatic malignancies［J］. J Vasc Interv Radiol， 2006， 17（2 Pt 1）： 217-223.
［22］ Stefanini GF， Amorati P， Biselli M， et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience［J］. Cancer， 1995， 75： 2427-2434.
［23］ Bruix J， Llovet JM， Castells A， et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma： results of a randomized， controlled trial in a single institution［J］. Hepatology， 1998， 27： 1578-1583.
［24］ Lo CM， Ngan H， Tso WK， et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma［J］. Hepatology， 2002， 35： 1164-1171.
［25］ Llovet JM， Real MI， Montana X， et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma： a randomised controlled trial［J］. Lancet， 2002， 359： 1734-1739.
［26］ Camma C， Schepis F， Orlando A， et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma： meta-analysis of randomized controlled trials［J］. Radiology， 2002， 224： 47-54.
［27］ Forner A， Llovet JM， Bruix J. Hepatocellular carcinoma［J］. Lancet， 2012， 379： 1245-1255.
［28］ Okusaka T， Okada S， Ueno H， et al. Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma［J］. Oncology， 2000， 58： 293-299.
［29］ Choi BI， Kim HC， Han JK， et al. Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma： CT and pathologic findings［J］. Radiology， 1992， 182： 709-713.
［30］ Lim HK， Han JK. Hepatocellular carcinoma： evaluation of therapeutic response to interventional procedures［J］. Abdom Imaging， 2002， 27： 168-179.
［31］ Kim HC， Chung JW， Lee W， et al. Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization［J］. Radiographics， 2005， 25： S25-S39.
［32］ Nakai M， Sato M， Kawai N， et al. Hepatocellular carcinoma： involvement of the internal mammary artery［J］. Radiology， 2001， 219： 147-152.
［33］ Abdel-Rahman O， Elsayed ZA. Combination trans arterial chemoembolization（TACE） plus sorafenib for the management of unresectable hepatocellular carcinoma： a systematic review of the literature［J］. Dig Dis Sci， 2013， 58： 3389-3396.
［34］ Kim HY， Park JW， Joo J， et al. Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma［J］. J Gastroenterol Hepatol， 2012， 27： 1051-1056.
［35］ 　阿布都外力·吾布力卡斯穆， 迪里木拉提·巴吾冬， 任伟新. 巴塞罗那肝癌B期患者TACE治疗的预后及生存分析［J］． 介入放射学杂志， 2014， 23： 441-445．
［36］ Kajihara J， Tomimaru Y， Eguchi H， et al. The clinical impact of transcatheter arterial chemoembolization（TACE）-induced c-Met upregulation on TACE refractoriness in hepatocellular carcinoma［J］. Dig Dis Sci， 2016， 61： 1572-1581.
［37］ Kudo M， Izumi N， Kokudo N， et al. Management of hepatocellular carcinoma in Japan： Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology（JSH） 2010 updated version［J］. Dig Dis， 2011， 29： 339-364.
［38］ Park JW， Amarapurkar D， Chao Y， et al. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma （EPOIHCC）［J］. Liver Int， 2013， 33： 327-337.
［39］ Raoul JL， Gilabert M， Piana G. How to define transarterial chemoembolization failure or refractoriness： a European perspective［J］. Liver Cancer， 2014， 3： 119-124.
［40］ Kudo M， Matsui O， Izumi N， et al. Transarterial chemoembolization failure/refractoriness： JSH-LCSGJ criteria 2014 update［J］. Oncology， 2014， 87（Suppl）： 22-31.
［41］ Sieghart W， Hucke F， Pinter M， et al. The ART of decision making： retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma［J］. Hepatology， 2013， 57： 2261-2273.
［42］ Ogasawara S， Chiba T， Ooka Y， et al. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization［J］. Oncology， 2014， 87： 330-341.
［43］ Ikeda M， Mitsunaga S， Shimizu S， et al. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization［J］. J Gastroenterol， 2014， 49： 932-940.
［44］ Llovet JM， Ricci S， Mazzaferro V， et al. Sorafenib in advanced hepatocellular carcinoma［J］. N Engl J Med， 2008， 359： 378-390.
［45］ Cheng AL， Kang YK， Chen Z， et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma： a phase Ⅲ randomised， double-blind， placebo-controlled trial［J］. Lancet Oncol， 2009， 10： 25-34.
［46］ Arizumi T， Ueshima K， Minami T， et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization （TACE） refractory and intermediate-stage hepatocellular carcinoma［J］. Liver Cancer， 2015， 4： 253-262.
［47］ Iwasa S， Ikeda M， Okusaka T， et al. Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization［J］. Jpn J Clin Oncol， 2011， 41： 770-775.
［48］ Poyanli A， Rozanes I， Acunas B， et al. Palliative treatment of hepatocellular carcinoma by chemoembolization［J］. Acta radiol， 2001， 42： 602-607.
［49］ Lee JK， Chung YH， Song BC， et al. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization［J］. J Gastroenterol Hepatol， 2002， 17： 52-58.
［50］ Song DS， Choi JY， Yoo SH， et al. DC bead transarterial chemoembolization is effective in hepatocellular carcinoma refractory to conventional transarteral chemoembolization： a pilot study［J］. Gut Liver， 2013， 7： 89-95.
［51］ Yu JI， Park HC， Lim DH， et al. Do biliary complications after hypofractionated radiation therapy in hepatocellular carcinoma matter?［J］. Cancer Res Treat， 2016， 48： 574-582.
［52］ Bush DA， Kayali Z， Grove R， et al. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma： a phase 2 prospective trial［J］. Cancer， 2011， 117： 3053-3059.
［53］ Ricke J， Wust P， Stohlmann A， et al. CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation： phase Ⅰ-Ⅱ results of a novel technique［J］. Int J Radiat Oncol Biol Phys， 2004， 58： 1496-1505.
［54］ Meigooni AS， Hayes JL， Zhang H， et al. Experimental and theoretical determination of dosimetric characteristics of IsoAid ADVANTAGE 125I brachytherapy source［J］. Med Phys， 2002， 29： 2152-2158.
［55］ Nath R， Melillo A. Dosimetric characteristics of a double wall 125I source for interstitial brachytherapy［J］. Med Phys， 1994， 20： 1475-1483.
［56］ 冉 琳， 任伯绪． 125I粒子组织间近距离放射治疗肝癌的现状与进展［J］． 介入放射学杂志， 2012， 21： 876-878．
［57］ 刘 健， 张福君， 吴沛宏， 等． CT导向下125I粒子植入治疗肝门区肝癌［J］． 介入放射学杂志， 2005， 14： 606-609．
［58］ Nag S， DeHaan M， Scruggs G， et al. Long term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy［J］. Int J Radiat Oncol Biol Phys， 2006， 64： 736-744.
［59］ Lü J， Cao XF， Zhu B. 125I Radioactive Seeds implantation therapy for hepatocellular carcinoma［J］. Gastroenterol Res， 2009， 2： 141-147.

相似文献/References:

[1]王惠文,刘瑞宝,刘　　　岩,等.原发性肝癌ＴＡＣＥ后ＦＡＫ、ＮＦκＢｐ６５表达及意义[J].介入放射学杂志,2011,(08):621.
　WANG Hui-wen,LIU Rui-bao,LIU Yan,et al.The expression and significance of FAK and NF-κBp65 in hepatocellular carcinoma after transcatheter arterial chemoembolization[J].journal interventional radiology,2011,(12):621.
[2]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(12):78.
[3]杨柏帅,施裕新,袁 敏,等.TACE治疗既往有肝功能衰竭史肝癌患者七例[J].介入放射学杂志,2014,(09):805.
　YANG Bo shuai,SHI Yu xin,YUAN Min,et al.TACE treatment for patients with inoperable hepatocellular carcinoma and hepatic failure history： initial experience in seven cases[J].journal interventional radiology,2014,(12):805.
[4]王以浪,王亚非,张 亮,等. 肝细胞癌患者TACE术前后血清miR- 21表达变化及临床意义[J].介入放射学杂志,2014,(05):406.
　WANG Yi- lang,WANG Ya- fei,ZHANG Liang,et al. The changes of serum miR- 21 expression level in patients with HCC before and after TACE and its clinical significance[J].journal interventional radiology,2014,(12):406.
[5]邢桃红,牛焕章,周媛媛,等. TACE联合索拉非尼治疗23例中晚期肝细胞肝癌的护理[J].介入放射学杂志,2014,(05):449.
　XING Tao- hong,NIU Huan- zhang,ZHOU Yuan- yuan,et al. Nursing for patients with advanced hepatocellular carcinoma receiving transcatheter arterial chemoembolization combined with sorafenib： initial experience in 23 cases[J].journal interventional radiology,2014,(12):449.
[6]阿布都外力·吾布力卡斯穆,迪里木拉提·巴吾冬,任伟新. 巴塞罗那肝癌B期患者TACE治疗的预后及生存分析[J].介入放射学杂志,2014,(05):435.
　ABUDUWAILI Obulikasimu,DILMURAT Bawudun,REN Wei- xin.. Transcatheter arterial chemoembolization for the treatment of Barcelona stage B hepatocellular carcinoma： analysis of the prognosis and survival[J].journal interventional radiology,2014,(12):435.
[7]尹芝兰,肖恩华.原发性肝癌行TACE术后对乙型肝炎病毒影响[J].介入放射学杂志,2014,(12):1114.
　YIN Zhi lan,XIAO En hua..The influence of TACE for primary hepatocellular carcinoma on hepatitis B virus[J].journal interventional radiology,2014,(12):1114.
[8]王 龙,张 勇,王亚运,等.125I粒子联合经导管动脉化疗栓塞治疗肝细胞肝癌伴门静脉癌栓临床有效性与安全性meta 分析[J].介入放射学杂志,2018,27(05):419.
　WANG Long,ZHANG Yong,WANG Yayun,et al.125I seed implantation combined with TACE for the treatment of HCC complicated by portal vein tumor thrombus： a meta- analysis of its clinical effectiveness and safety[J].journal interventional radiology,2018,27(12):419.
[9]李 征,米登海,杨克虎,等.经动脉化疗栓塞联合微波消融治疗肝癌有效性和安全性的系统评价[J].介入放射学杂志,2015,(11):957.
　LI Zheng,MI Deng- hai,YANG Ke- hu,et al.Effectiveness and safety of TACE combined with MWA for primary hepatic cancer： a systematic review[J].journal interventional radiology,2015,(12):957.
[10]许 贇,沈 强,王 能,等.微波消融治疗＞70岁早期肝细胞肝癌患者效果分析[J].介入放射学杂志,2016,(04):332.
　XU Yun,SHEN Qiang,WANG Neng,et al.Effect analysis of microwave ablation therapy for early hepatocellular carcinoma in patients over 70 years old[J].journal interventional radiology,2016,(12):332.
[11]杨柏帅,施裕新,袁 敏,等.终末期肾衰竭肝癌患者TACE术中应用洛铂治疗3例[J].介入放射学杂志,2016,(05):381.
　YANG Bo- shuai,SHI Yu- xin,YUAN Min,et al.Transcatheter arterial chemoembolization using lobaplatin and lipiodol for the treatment of hepatocellular carcinoma associated with end- stage renal failure： report of three cases[J].journal interventional radiology,2016,(12):381.
[12]赵 倩,颜志平.载药微球经导管动脉化疗栓塞治疗肝癌研究进展 [J].介入放射学杂志,2017,(11):1052.
　ZHAO Qian,YAN Zhiping.Transarterial chemoembolization with drug- eluting beads for the treatment of hepatocellular carcinoma： recent progress in research[J].journal interventional radiology,2017,(12):1052.
[13]徐 圣,张学军,石宝琪,等.微波消融联合经导管动脉化疗栓塞术治疗肝细胞癌生存预测[J].介入放射学杂志,2020,29(05):508.
　XU Sheng,ZHANG Xuejun,SHI Baoqi,et al.The survival prediction for HCC patients receiving microwave ablation combined with TACE[J].journal interventional radiology,2020,29(12):508.
[14]荆 霞,徐 圣.Callispheres栓塞后综合征的综合护理模式与常规护理模式比较[J].介入放射学杂志,2020,29(07):722.
　JING Xia,XU Sheng..Comprehensive nursing mode versus routine nursing mode for post- embolization syndrome in HCC patients after DEB- TACE： a comparative study[J].journal interventional radiology,2020,29(12):722.
[15]沈建东,戴 锋,王 斌,等.磷脂酰肌醇-4，5-二磷酸肌醇-3-激酶对原发性肝癌TACE治疗反应的预测作用[J].介入放射学杂志,2024,33(04):382.
　SHEN Jiandong,DAI Feng,WANG Bin,et al.The application of PIK3CA in predicting the efficacy of TACE in the treatment of primary liver cancer[J].journal interventional radiology,2024,33(12):382.

备注/Memo

备注/Memo:
（收稿日期：２０１7-０4-13）
（本文编辑：边 佶）
更新日期/Last Update: 2017-12-24